ISSN (Print) - 0012-9976 | ISSN (Online) - 2349-8846

A+| A| A-

Denmur Fax Roll

Dabur India INCORPORATED in 1975, Dabur India is one of the leading diversified multidivi- sional companies in the pharmaceutical and personal care industries with a range of over 450 products. The company is ranked 56th in terms of net profit and 25th in terms of book value and earnings per share among the top 150 Indian companies (The Economic Times, August 16, 1993). Further, with an earnings per share of Rs 20.1 for the year ended March 31, 1993, it stands well ahead of established pharmaceutical companies like Ranbaxy, Boots Pharma, Hoechst, Burroughs Wellcome and Sandoz. Promoted by A C Burman, G C Burman, Pradip Burman and Anand C Burman, the company has six divisions, namely, a health care products division which manufactures ayurvedic and OTC medicines including health tonics, digestives, laxatives, revitalisers, health foods and a range of products for various disorders, a family products division which manufactures cosmetics, toiletry articles and food items, a natural gums division which manufactures guargum and allied chemicals, an exports division, a pharmaceutical division which is engaged in ethical allopathic medicines and bulk drugs for both Indian and export markets and a veterinary division which produces health care products, ayurvedic medicines and animal health care products with a range of ayurvedic specialities. For the past three years, the company has contributed over 15 per cent of its profit after tax to research and developed over 50 drugs and formulations including a critical intermediate chemical used in the formulations of a specialised anti-cancer drug named taxol. The company has a gross annual turnover of Rs 261 crore and is a profit making, dividend paying company. It has two subsidiaries, namely, Interx Laboratories and Dabur Nepal. Interx Laboratories further has two subsidiaries, namely, Excellent India and Moonlight Ranch. The company now proposes to set up a phytopharma project for manufacture of anti-cancer drug taxol, chemical intermediary for cancer drug and terfenadine, a non- sedative anti-allergic drug. The company is setting up a manufacturing unit in Himachal Pradesh. In addition the company plans to modernise its Sahibabad unit by installing various balancing equipment, mechanising certain operations, installing a reverse osmosis plant, a concentration plant for extraction of extracts from various herbs, barks, roots, seeds, etc, expanding the storage space and also installing two additional D G sets of 1,000 kva each. To finance these projects, the company is entering the capital market with an issue of 57,00,000 equity shares of Rs 10 each at a premium of Rs 85 per share. The issue, which will be lead managed by PNB Capital Services, Kotak Mahindra Finance and IFCI, is slated to open for public subscription on November 2.

To read the full text Login

Get instant access

New 3 Month Subscription
to Digital Archives at

₹826for India

$50for overseas users

Comments

(-) Hide

EPW looks forward to your comments. Please note that comments are moderated as per our comments policy. They may take some time to appear. A comment, if suitable, may be selected for publication in the Letters pages of EPW.

Back to Top